Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2010
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
M Joerger, K Matter-Walstra, M Früh, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 18, 2020
Choice of first line systemic treatment in pancreatic cancer among national experts
M Glatzer, D Horber, M Montemurro, et al.
British Journal of Cancer
|
October 13, 2006
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
S Leyvraz, R Herrmann, L Guillou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 4, 2005
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
G W Goerres, R Stupp, G Barghouth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
V Hess, S Pratsch, S Potthast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)
M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Haematology
|
April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
R A Stahel, L M Jost, T Kroner, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer
S Hussung, D Akhoundova, C Pistoni, et al.
Clinical and Translational Radiation Oncology
|
February 18, 2021
The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas
S J Rogers, N R Datta, E Puric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
M Borner, D Koeberle, R Von Moos, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2010
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
M Joerger, K Matter-Walstra, M Früh, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
April 18, 2020
Choice of first line systemic treatment in pancreatic cancer among national experts
M Glatzer, D Horber, M Montemurro, et al.
British Journal of Cancer
|
October 13, 2006
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
S Leyvraz, R Herrmann, L Guillou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 4, 2005
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
G W Goerres, R Stupp, G Barghouth, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2010
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
V Hess, S Pratsch, S Potthast, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)
M M Borner, M Castiglione, M Bacchi, et al.
British Journal of Haematology
|
April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission
R A Stahel, L M Jost, T Kroner, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer
S Hussung, D Akhoundova, C Pistoni, et al.
Clinical and Translational Radiation Oncology
|
February 18, 2021
The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas
S J Rogers, N R Datta, E Puric, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2008
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
M Borner, D Koeberle, R Von Moos, et al.
Page
of 3